Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Ordinary Shares, Nominal value 0.12 per share
-
Shares outstanding
-
112M
-
Number of holders
-
20
-
Total 13F shares, excl. options
-
33.3M
-
Shares change
-
-170K
-
Total reported value, excl. options
-
$445M
-
Value change
-
+$689K
-
Number of buys
-
12
-
Number of sells
-
-3
-
Price
-
$13.26
Significant Holders of NewAmsterdam Pharma Co N.V. - Ordinary Shares, Nominal value 0.12 per share (NAMS) as of Q1 2023
23 filings reported holding NAMS - NewAmsterdam Pharma Co N.V. - Ordinary Shares, Nominal value 0.12 per share as of Q1 2023.
NewAmsterdam Pharma Co N.V. - Ordinary Shares, Nominal value 0.12 per share (NAMS) has 20 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33.3M shares
of 112M outstanding shares and own 29.71% of the company stock.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (9.34M shares), Bain Capital Life Sciences Investors, LLC (8.3M shares), RA CAPITAL MANAGEMENT, L.P. (4M shares), VIKING GLOBAL INVESTORS LP (3.92M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.54M shares), Medicxi Ventures Management (Jersey) Ltd (2M shares), BVF INC/IL (1.52M shares), GMT CAPITAL CORP (1.08M shares), Ensign Peak Advisors, Inc (355K shares), and Parkman Healthcare Partners LLC (115K shares).
This table shows the top 20 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.